{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:51:30Z","timestamp":1792198290339,"version":"4.4.0"},"reference-count":66,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The acute myeloid leukemia (AML) treatment landscape has changed substantially since 2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2, midostaurin and gilteritinib to target FLT3, and ivosidenib and enasidenib to target mutant isocitrate dehydrogenase 1 and 2, respectively. Other additions include reapproval of gemtuzumab ozogomycin to target CD33, glasdegib to target the hedgehog pathway, and a liposomal formulation of daunorubicin and cytarabine (CPX-351). Genomically heterogeneous AML has a tendency to evolve, particularly under selective treatment pressure. For decades, treatment decisions have largely centered around chemotherapy drug intensity. Physicians now have access to an increasing number of drugs with novel mechanisms of action and distinctive side-effect profiles. Key issues faced by hematologists in this era of new drugs include (1) the timely identification of actionable mutations at diagnosis and at relapse; (2) deciding which drug to use among several therapeutic options; and (3) increasing awareness of how to anticipate, mitigate, and manage common complications associated with these new agents. This article will use 3 case presentations to discuss some of the new treatment challenges encountered in AML management, with the goal of providing practical guidance to aid the practicing physician.<\/jats:p>","DOI":"10.1182\/blood.2019001239","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T17:58:38Z","timestamp":1574704718000},"page":"85-96","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":260,"title":["How I treat acute myeloid leukemia in the era of new drugs"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"first","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Haematology, The Alfred Hospital and Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"22","key":"2020010911590747700_B1","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020010911590747700_B2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2020010911590747700_B3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","article-title":"Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older","volume":"103","author":"Prassek","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"2020010911590747700_B4","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"issue":"21","key":"2020010911590747700_B5","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020010911590747700_B6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"2020010911590747700_B7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15","key":"2020010911590747700_B8","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020010911590747700_B9","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.clml.2018.07.052","article-title":"Cytogenetic and molecular drivers of outcome with venetoclax-based combination therapies in treatment-naive elderly patients with acute myeloid leukemia (AML) [abstract]","volume":"18","author":"Strickland","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2020010911590747700_B10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3324\/haematol.11575","article-title":"Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model","volume":"93","author":"Montesinos","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"2020010911590747700_B11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"issue":"10","key":"2020010911590747700_B12","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.3324\/haematol.2018.189886","article-title":"NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents","volume":"103","author":"Prata","year":"2018","journal-title":"Haematologica"},{"issue":"23","key":"2020010911590747700_B13","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2020010911590747700_B14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"2020010911590747700_B15","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2020010911590747700_B16","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/bloodadvances.2018020305","article-title":"Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia","volume":"2","author":"Sakaguchi","year":"2018","journal-title":"Blood Adv"},{"issue":"8","key":"2020010911590747700_B17","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2012-02-410746","article-title":"All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)","volume":"120","author":"Iland","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2020010911590747700_B18","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.leu.2403790","article-title":"Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group","volume":"19","author":"Callens","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"2020010911590747700_B19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9825","key":"2020010911590747700_B20","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"2020010911590747700_B21","doi-asserted-by":"crossref","first-page":"916","DOI":"10.18632\/oncotarget.1536","article-title":"Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial","volume":"5","author":"Renneville","year":"2014","journal-title":"Oncotarget"},{"issue":"15","key":"2020010911590747700_B22","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.18632\/oncotarget.2196","article-title":"MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin","volume":"5","author":"Lambert","year":"2014","journal-title":"Oncotarget"},{"issue":"17","key":"2020010911590747700_B23","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","article-title":"The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia","volume":"127","author":"Olombel","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2020010911590747700_B24","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2002-02-0420","article-title":"Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors","volume":"100","author":"Kottaridis","year":"2002","journal-title":"Blood"},{"issue":"suppl 1","key":"2020010911590747700_B25","first-page":"182","article-title":"Clonal evolution of FLT3-ITD positive AML in patients treated with midostaurin in combination with chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 trials [abstract]","volume":"130","author":"Schmalbrock","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2020010911590747700_B26","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"issue":"suppl 13","key":"2020010911590747700_B27","article-title":"Gilteritinib significantly prolongs overall survival in patients with FLT3-mutate relapsed\/refractory acute myeloid leukemia: results from the phase 3 Admiral trial [abstract]","volume":"79","author":"Perl","year":"2019","journal-title":"Cancer Res"},{"issue":"22","key":"2020010911590747700_B28","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V128.22.1069.1069","article-title":"Final results of the chrysalis trial: a first-in-human phase 1\/2 dose-escalation, dose-expansion study of gilteritinib (ASP2215) in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML) [abstract]","volume":"128","author":"Perl","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2020010911590747700_B29","first-page":"2705","article-title":"Evaluation of the impact of minimal residual disease, FLT3 allelic ratio, and FLT3 mutation status on overall survival in FLT3 mutation-positive patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) in the Chrysalis phase 1\/2 study [abstract]","volume":"130","author":"Levis","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2020010911590747700_B30","first-page":"566","article-title":"Low relapse rate in younger patients \u226460 years old with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) treated with crenolanib and cytarabine\/anthracycline chemotherapy [abstract]","volume":"130","author":"Wang","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020010911590747700_B31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ajh.24974","article-title":"Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia","volume":"93","author":"Altman","year":"2018","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2020010911590747700_B32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood-2018-99-110975","article-title":"Updated results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia (AML) [abstract]","volume":"132","author":"Pratz","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2020010911590747700_B33","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"issue":"suppl 1","key":"2020010911590747700_B34","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2018-99-110976","article-title":"Multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3 mutated (FLT3mut+) acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy: findings from the safety cohort [abstract]","volume":"132","author":"Esteve","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2020010911590747700_B35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"2020010911590747700_B36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells [published correction appears in Nat Med. 2018;24(4):526]","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2020010911590747700_B37","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2018-99-112614","article-title":"Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre Sormain trial [abstract]","volume":"132","author":"Burchert","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2020010911590747700_B38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1365-2141.2012.09076.x","article-title":"Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure","volume":"157","author":"Pr\u00e9bet","year":"2012","journal-title":"Br J Haematol"},{"issue":"17","key":"2020010911590747700_B39","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/bloodadvances.2017008227","article-title":"Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis","volume":"1","author":"Boddu","year":"2017","journal-title":"Blood Adv"},{"issue":"16","key":"2020010911590747700_B40","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/bloodadvances.2018015529","article-title":"Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia","volume":"2","author":"Ball","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"2020010911590747700_B41","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/ajh.24780","article-title":"Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: single institution experience","volume":"92","author":"Nanah","year":"2017","journal-title":"Am J Hematol"},{"issue":"22","key":"2020010911590747700_B42","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1182\/blood.V128.22.5058.5058","article-title":"Prognostic significance of IDH1 and IDH2 mutations in older patients with primary cytogenetically normal acute myeloid leukemia [abstract]","volume":"128","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2020010911590747700_B43","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"issue":"25","key":"2020010911590747700_B44","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"2020010911590747700_B45","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1200\/JCO.2019.37.15_suppl.7011","article-title":"Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML) [abstract]","volume":"37","author":"Dinardo","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020010911590747700_B46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01.HS9.0000559376.17429.23","article-title":"A phase 1b\/2 clinical study of targeted IDH1 inhibition with ivosidenib, in combination with the BCL-2 inhibitor venetoclax, for patients with IDH1-mutated (mIDH1) myeloid malignancies: PF291 [abstract]","volume":"3","author":"Dinardo","year":"2019","journal-title":"HemaSphere"},{"issue":"8","key":"2020010911590747700_B47","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"25","key":"2020010911590747700_B48","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2009-07-216457","article-title":"How I treat acute promyelocytic leukemia","volume":"114","author":"Tallman","year":"2009","journal-title":"Blood"},{"issue":"17","key":"2020010911590747700_B49","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2010-05-260117","article-title":"How I treat acute myeloid leukemia","volume":"116","author":"Rowe","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2020010911590747700_B50","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1182\/blood-2012-04-424440","article-title":"How I treat hematologic emergencies in adults with acute leukemia","volume":"120","author":"Zuckerman","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2020010911590747700_B51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2020010911590747700_B52","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2020010911590747700_B53","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","article-title":"How I treat hyperleukocytosis in acute myeloid leukemia","volume":"125","author":"R\u00f6llig","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020010911590747700_B54","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2016-01-635060","article-title":"How I treat acute myeloid leukemia presenting with preexisting comorbidities","volume":"128","author":"Ofran","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020010911590747700_B55","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood-2016-09-693648","article-title":"How I treat FLT3-mutated AML","volume":"129","author":"Pratz","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2020010911590747700_B56","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2020010911590747700_B57","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V126.23.6.6","article-title":"The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)\/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603\/RATIFY [Alliance]) [abstract]","volume":"126","author":"Stone","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2020010911590747700_B58","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020010911590747700_B59","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.3324\/haematol.2018.198614","article-title":"Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group","volume":"103","author":"Ad\u00e8s","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2020010911590747700_B60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"suppl 15","key":"2020010911590747700_B61","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.1200\/JCO.2019.37.15_suppl.7028","article-title":"Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): updated results from a phase 1 study [abstract]","volume":"37","author":"Roboz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020010911590747700_B62","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2020010911590747700_B63","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1086\/376609","article-title":"Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome","volume":"73","author":"Siegel","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"8","key":"2020010911590747700_B64","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-018-0115-6","article-title":"Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib","volume":"24","author":"Quek","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"2020010911590747700_B65","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"issue":"7712","key":"2020010911590747700_B66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","article-title":"Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations","volume":"559","author":"Intlekofer","year":"2018","journal-title":"Nature"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/2\/85\/1550967\/bloodbld2019001239c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/2\/85\/1550967\/bloodbld2019001239c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T07:00:24Z","timestamp":1612594824000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/2\/85\/428884\/How-I-treat-acute-myeloid-leukemia-in-the-era-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001239","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]}}}